Oroszlány, Hungary

Adrienn Palvolgyi

This inventor holds 1 USPTO granted patent. Top assignee: Egis Gyogyszergyar Zrt.. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adrienn Palvolgyi. Retrieved from https://idiyas.com/inventor/adrienn-palvolgyi

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 18.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adrienn Palvolgyi: Innovator in Pharmaceutical Chemistry

Adrienn Palvolgyi is a notable inventor based in Oroszlany, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly with his innovative work on compounds that target the central GABAergic system.

Latest Patents

Adrienn holds a patent for "Dihydro-oxazinobenzodiazepine compounds, a process for their preparation and pharmaceutical compositions containing them." This patent describes compounds of formula (I) that exhibit a selective dual action on the central GABAergic system, along with the processes for their preparation and the pharmaceutical compositions that include them. He has 1 patent to his name.

Career Highlights

Adrienn is currently employed at Egis Gyogyszergyar Zrt., a prominent pharmaceutical company in Hungary. His work at Egis has allowed him to focus on developing innovative solutions in the pharmaceutical sector, contributing to advancements in medication and treatment options.

Collaborations

Throughout his career, Adrienn has collaborated with talented professionals, including Agnes Kenez and Ferenc Bertha. These collaborations have fostered a creative environment that encourages the exchange of ideas and the development of groundbreaking pharmaceutical innovations.

Conclusion

Adrienn Palvolgyi's contributions to pharmaceutical chemistry highlight the importance of innovation in developing effective treatments. His work continues to impact the field positively, showcasing the potential of targeted compounds in medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…